We hypothesized that the use of a lower vector dose with a codon-optimized SMN1 transgene (co-hSMN1) would restore SMN expression close to physiological levels in relevant organs, providing an improved risk to benefit ratio for SMA patients. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.